Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment?

Nature Clinical Practice Rheumatology volume 2, pages 408–409 (2006)Cite this article

boxed-textEmery P et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54: 1390–1400

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. McLaughlin P et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clinc Oncol 16: 2825–2833

    Article  CAS  Google Scholar 

  2. Looney RJ et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus. Arthritis Rheum 50: 2580–2589

    Article  CAS  Google Scholar 

  3. Baert F et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601–608

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Rheumatology Fellow in and MH Weisman is the Director of the Division of Rheumatology, Cedars–Sinai Medical Center, Los Angeles, CA, USA

    Catherine B Driver & Michael H Weisman

Authors
  1. Catherine B Driver
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael H Weisman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael H Weisman.

Ethics declarations

Competing interests

Dr Catherine B Driver owns stock in Amgen.

Dr Michael H Weisman is involved in research support for Amgen, Abbott, Bristol Myers Squibb (BMS), Centocor, Genentech, Human Genome Sciences (HGS), PDL. Dr Weisman is also involved as a Consultant and on the Advisory Boar for Abbott, Bristol Myers Squibb (BMS), Coley Pharmaceutical, ELAN, Human Genome Sciences (HGS), Rigel, Roche, Vertex Pharmaceutical, and UCB Pharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Driver, C., Weisman, M. Is rituximab a safe and effective treatment for patients with active RA, irrespective of methotrexate treatment?. Nat Rev Rheumatol 2, 408–409 (2006). https://doi.org/10.1038/ncprheum0255

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0255

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing